Evidence map›Paper›PMID 39263951›Full record

ArticleFuture oncology (London, England)2024

Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study.

Isabel María Carrión-Madroñal, Rocío Díaz-Acedo, Santiago José Lora-Escobar, Eloisa Naranjo-Llamas, Didiana Jaramillo-Ruiz, Silvia Artacho-Criado, Elena Prado-Mel

Abstract readMulticenter Study
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. A Pyrone Glucoside fromBiomolecules · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Isabel María Carrión-MadroñalServicio de Farmacia, Hospital Universitario Virgen Macarena, Seville, 41009, SPAIN.ORCID 0000-0002-6462-2437
Rocío Díaz-AcedoServicio de Farmacia, Hospital Universitario Virgen del Rocío, Seville, 41013, SPAIN.ORCID 0000-0002-7186-0572
Santiago José Lora-EscobarServicio de Farmacia, Hospital Universitario Virgen del Rocío, Seville, 41013, SPAIN.ORCID 0000-0001-8255-8523
Eloisa Naranjo-LlamasServicio de Farmacia, Hospital Universitario Virgen de Valme, Seville, 41014, SPAIN.
Didiana Jaramillo-RuizServicio de Farmacia, Hospital Universitario Virgen del Rocío, Seville, 41013, SPAIN.ORCID 0000-0003-0898-1723
Silvia Artacho-CriadoServicio de Farmacia, Hospital Universitario Virgen de Valme, Seville, 41014, SPAIN.ORCID 0000-0001-6099-7365
Elena Prado-MelServicio de Farmacia, Hospital Universitario Virgen del Rocío, Seville, 41013, SPAIN.ORCID 0000-0003-3654-0247

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedCamptothecinImmunoconjugatesTriple Negative Breast NeoplasmsAdultAgedFemaleHumansMiddle AgedNeoplasm MetastasisTreatment OutcomeAntibodies, Monoclonal, HumanizedCamptothecinImmunoconjugatessacituzumab govitecaneffectivenessmetastatic triple negative breast cancerreal world datasacituzumab-govitecansafety

Identifiers

PMID39263951
PMCPMC11534107

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.